Bisa Revolusi ing perawatan kanker

Possible Revolution in Cancer Treatment

Temonan bisa ngidini pangobatan pribadi kuat kang patients Perdana 'sistem imun dhewe kanggo nyerang pelaku biologi ing tumors


Powered by Guardian.co.ukArtikel iki judul “génétika tumor kanker mbukak bisa revolusi perawatan” ditulis déning Ian Sample editor Ilmu, kanggo Guardian ana 4 Maret 2016 07.08 UTC

A ditemokaké landmark menyang susunan genetika saka tumors wis potensial kanggo mbukak ngarep anyar ing perang ing kanker, ngirimke terapi kuat sing ngarang patients individu, ilmuwan wis ngandika.

temonan rawuh saka riset menyang kerumitan genetik saka paru-paru lan kulit kanker kang ketemu sing kaya tumor tuwuh lan panyebaran ing awak, padha nindakake karo wong-wong mau sawetara biologi "panji" sing sistem imun bisa langsung kanggo nyerang.

Amarga panji, kang katon protein lumahing, sing ditemokaké mung ing sel kanker, padha nyedhiyani apa ilmuwan diterangake minangka "target kepileh" kanggo terapi anyar sing digambar ing daya saka sistem imun kanggo pertempuran kanker.

Pangobatan sing sabuk sistem imun wis ditampilake gedhe janji marang sawetara Wangun kanker, kayata melanoma, nanging padha ora bisa ing wong.

Salah pendekatan pers rem ing sistem imun, unleashing pasukan lengkap ing sel T pembunuh, kang digunakake dampened mudhun dening sel-sel kanker. Nanging bisa, sistem imun sabar kudu ngenali kanker minangka mungsuh.

Charles Swanton, pakar ing évolusi kanker sing mimpin sinau paling anyar ing Institut Francis Crick ing London, ngandika panemon protein lumahing sambungan dening kabeh sel kanker sabar kang nglebokaké "Achilles hak" kanggo terapi mangsa kanggo target.

Carane imun karya sel perawatan
Carane imun karya sel perawatan

Tim internasional, nglibatno ilmuwan saka Harvard, MIT lan Universitas College London, ketemu sing patients ing sinau wis dibukak reaksi imun marang kanker sing. Nanging serangan padha banget ringkih numpes sel mbebayakake. Close pengawasan saka tumors dicethakaké kekebalan disarèkaké nang wong: sawetara wis dikenali panji unik kanker kang, nanging padha salah siji sulap, asor utawa kalah pertahanan kanker kang.

"Apa kita wis ketemu kanggo pisanan iku tumors ateges sow wiji saka karusakan dhewe. Lan sing ing tumors, ana sèl imun sing kenal sing panji kang saiki ing saben sel tumor,"Ngandika Swanton.

Minangka tumors tuwuh, padha mekar. Swara wektu, wujud scramble DNA ing, lan siji bagéan saka tumor wiwit katon beda banget kanggo liyane. Nanging Swanton ketemu sing sel tumor malah Komplek bisa metokake hallmarks saka sing asli. Nulis ing jurnal, Ilmu, kang nggambarake, ing loro patients kanker paru-paru, protein lumahing wis mutated awal lan muncul ing saindhenging tumor.

karya, mbiayai dening Cancer Research UK lan Rosetrees Trust, ngundakake loro rute bisa kanggo nambani kanker patients mangsa. Ing siji skenario, Doctors bisa njupuk biopsi saka tumor sing sabar kang, maca génom lan bisa metu kang panji sing saiki ing kabeh sel mbebayakake. Yen padha golek kekebalan nang tumor sing kenal gendéra, padha saged dados kathah ing Lab, lan banjur maneh infused menyang sabar, prodhuksi serangan tliti akeh banget ing sel kanker. Ing skenario liyane, panji protein piyambak bisa digunakake kanggo gawe vaksin sing nglawan kanker. Inject mau menyang awak, lan sel kekebalan ngenali minangka invaders lan miwiti serangan. ing laku, ing terapi anyar kudu digunakake kajawi obatan ana disebut "inhibitor papriksan" sing mungkasi kanker neutralizing sel T.

Swanton, sinau kang katon ing Ilmu, ngarep-arep kanggo miwiti nyoba manungsa pisanan ing patients paru loro kanggo telung taun. penyakit punika pembunuh kanker paling gedhe UK, ngakoni luwih saka 35,000 urip taun. Sampeyan ora cetho apa perawatan bakal bisa, nanging ilmuwan pracaya iku wis kasempatan luwih apik yen sistem imun target kaping panji ing tumor sing. "Kita wis ora mbuktekaken sing iki bisa impact ing care sabar. Apa kita wis ditampilake sing ana terapi unik potensi saiki ing tumor saben sabar kang,"Ngandika Swanton. "Iki njupuk medicine pribadi kanggo watesan Absolute."

ing perawatan, yen dianggo ing kabeh, Koyone dadi paling efektif ing kanker sing duwe akèh wujud, kayata melanoma lan kanker paru-paru-related udud. Nanging ilmuwan rencana riset luwih kanggo neliti apa bisa èfèktif marang kanker kurang mutated, kayata nguyuh, prostat lan kanker pankreas. Swanton wis ora Karang prosedur, but conceded that it not be cheap.

David Adams, a cancer geneticist at the Wellcome Trust Sanger Institute, said the research could help doctors work out who is most likely to benefit from new therapies that exploit the immune system. “The greatest use of this knowledge is in working out which patients are most likely to be treatable,"Ngandika. “The issue with these immunotherapies is they are extremely expensive and we don’t know who will respond and who won’t.”

But he said more patients would have to be studied before the potential for developing a therapy was clear. “The opportunity here is to be able to identify T-cells within tumours that react with trunkal flags, to expand these T-cells in culture, and re-introduce these cells back into patients to target the patient’s tumour. This is the epitome of personalised therapy,"Ngandika.

“This work is right on the cutting edge. The next stage will be to expand the approach to larger cohorts and to use it as part of clinical trials,"Kang ditambahake.

guardian.co.uk © Guardian News & Media Limited 2010

Artikel web